Vistusertib

Drug Profile

Vistusertib

Alternative Names: AZD 2014

Latest Information Update: 07 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Cambridge University Hospitals; Netherlands Cancer Institute; NHS Greater Glasgow and Clyde; University of Birmingham; University of London; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Benzamides; Cytostatics; Morpholines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Diffuse large B cell lymphoma; Gastric cancer; Meningioma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Phase I/II Breast cancer; Fallopian tube cancer; Glioblastoma; Peritoneal cancer
  • Phase I Prostate cancer
  • No development reported Advanced breast cancer
  • Discontinued Renal cancer

Most Recent Events

  • 06 Jul 2017 AstraZeneca completes a phase I trial for Solid tumours (Monotherapy, Combination therapy, Late-stage disease, Second-line therapy or greater) in United Kingdom (NCT02640755)
  • 06 Jun 2017 Adverse event data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Adverse events and efficacy data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO - 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top